Herceptin Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
Conditions: Breast Cancer; Metastatic Breast Cancer; HER2-positive Breast Cancer; Gastric Cancer; Metastatic Gastric Cancer; HER2-positive Gastric Cancer Intervention: Diagnostic Test: 89Zr-DFO*-trastuzumab PET scan Sponsors: Amsterdam UMC, location VUmc; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2023 Category: Research Source Type: clinical trials

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
Condition: HER2-positive Breast Cancer Intervention: Drug: Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab) Sponsors: Institut Curie; Seagen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2023 Category: Research Source Type: clinical trials

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab Deruxtecan Sponsors: Daiichi Sankyo, Inc.; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 18, 2023 Category: Research Source Type: clinical trials

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab emtansine Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials